 NEW YORK--BUSINESS WIRE--Holocene Advisors, LP Holocene, a fundamental investment management firm and significant shareholder of Acceleron Pharma Inc. Nasdaq: XLRN Acceleron or the Company, today announced that it does not intend to tender its shares into Merck Co.s NYSE: MRK proposed 180 per share offer for the Company announced on September 30, 2021. Holocene stated the following: As a large shareholder in Acceleron, we believe the Companys management team has done a 